Pharmafile Logo
Pharmafocus logo
Advanced Search

glioblastoma

Showing 8 posts of 8 posts found.

Chemotherapy

FDA grants ODD to ABM Therapeutics’ treatment for patients with glioblastoma

August 3, 2023
Medical Communications ABM Therapeutics, ABM-1310, FDA, Oncology, glioblastoma

ABM Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310. …

News
shutterstock

Scorpion venom added to CAR-T therapy increases efficacy in brain cancer, research shows

March 6, 2020
Medical Communications, Research and Development CAR-T, Cancer, brain cancer, glioblastoma, pharma

Chimeric antigen receptor T cell (CAR-T) therapy has gained much traction and attention in the past years for its innovative …

News

MS drug boosts effectiveness of cancer therapy in treating glioblastoma, study shows

August 9, 2019
Medical Communications MS, brain cancer, glioblastoma, oncology, pharma

The multiple sclerosis (MS) drug teriflunomide boosts the effectiveness of cancer drugs in treating glioblastoma, according to researchers from UC, …

News
abbvie_0

AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit

May 20, 2019
Research and Development, Sales and Marketing AbbVie, Cancer, Depatux-M, glioblastoma, pharma, trial failure

AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed …

News
vbl-big

VBL Therapeutics’ shares plummet on Phase 3 glioblastoma failure

March 9, 2018
Medical Communications, Research and Development VBL, VBL Therapeutics, glioblastoma, pharma, trial failure

Israeli drug development firm VBL Therapeutics has been left reeling after it announced that its lead oncology product ofranergene obadenovec, …

News
glioblastoma

ImmunoCellular awarded $19.9 million grant for ICT-107 phase 3 trial for glioblastoma

September 25, 2015
Research and Development California Institute for Regenerative Medicine, Cancer, ICT-107, brain cancer, glioblastoma

ImmunoCellular Therapeutics has been awarded a $19.9 million grant by California Institute for Regenerative Medicine (CIRM), California’s stem cell agency, …

News

Merck KGaA readies phase III brain cancer trial

June 13, 2011
Research and Development Merck KGaA, brain cancer, cilengitide, glioblastoma

Merck KGaA has completed patient enrollment for a phase III global trial of its first-in-class integrin inhibitor in a rare …

News

Brain cancer vaccine to move into phase III

November 24, 2010
Research and Development, Sales and Marketing Celldex, Pfizer, brain cancer, glioblastoma

Celldex will press ahead with large-scale trials of its vaccine treatment for brain cancer after encouraging phase II results. The …

News

Latest content

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023